Le Lézard
Classified in: Ebola virus, Health
Subject: SVY

Europe Point of Care Testing Devices Market is Expected to Reach EUR 7.2 Billion by 2022 Owing to Promising Growth in Demand of Infectious, Cardiac and Drug of Abuse POCT Devices: Ken Research


GURUGRAM, India, July 17, 2018 /PRNewswire/ --

Key Takeaway from Ken Research Report titled, "Europe POCT Devices Market Outlook to 2022"

POCT market in Europe has been estimated to grow registering a CAGR of close to 6% in the forecast period. This growth would be supported by the launch of new products, entry of new players, innovative technological revolution and increase in reliability on POCT products by home patients & institutional buyers. Technology innovation in molecular diagnostics is a major driver within the infectious disease POCT for HAIs and STDs. HIV-1, HCV, c.difficle, Chlamydia, H. Pylori, Strep A/B, Influenza A/B, RSV, Ebola and Zika have widespread in Europe during the review period. Highly sensitive cardiac troponins that are the efficacy equivalent to centralized lab testing will increase the adoption of POC cardiac markers in POC settings. CK-MB, myoglobin, BNP, NT-proBNP and D-dimers are simultaneously being used in emergency settings. Inevitable pharamcoeconomic benefits in POC cardiac testing propels this segment to achieve its highest growth potential. Increase in reliability & trust in POCT devices by home users & hospitals, more incidence of diseases such as HIV, infectious, cardiac and others, increase in the number of hospitals, clinics, pathology labs in Europe, growth in nano technology and chip-on-phone miniaturization would provide major thrust to the market.

     (Logo: https://mma.prnewswire.com/media/661352/Ken_Research_Logo.jpg )

Ken Research in its latest study "Europe POCT Devices Market Outlook to 2022 - by Geography (Western Europe & Eastern Europe), by Product (Blood Glucose POCT, Infectious POCT, Cardiac POCT, Rapid Coagulation POCT, Blood Gas & Electrolytes POCT, Hematology POCT, Pregnancy POCT, Urinalysis POCT, Cholesterol POCT, Fecal Occult POCT, Hb1Ac POCT & Drugs of Abuse POCT), by Customer Segments (Hospitals & Clinics, Diagnostics Labs & Primary Care Units and Homecare & Patients)" suggests that the demand for POCT devices would continue to grow owing to rising health awareness, launch of various new POCT products and expanding sales through internet portals.

Keywords  

Key Topics Covered: 

Key Companies Covered: 

For more information on the research report, refer to below link:

https://www.kenresearch.com/healthcare/medical-devices/europe-poct-devices-market/149664-91.html

Related Reports by Ken Research 

Vietnam Medical Devices Market Outlook to 2022 - By Equipments (Consumables, Diagnostic Imaging, Dental Products, Orthopedics and Prosthetics, Patient Aids and Other Medical Devices) 

The report provides a comprehensive analysis of Vietnam Medical Devices Market Overview and Size, growth drivers and restraints. 

Indonesia Medical Devices Market Outlook to 2022 - By Medical Consumable Products, Diagnostic Imaging Products, Auxiliary Devices, Orthopedic Implants, Dental Products, Aesthetic Devices, By Imports & Domestic Production 

The report provides information on medical device market segment, competitive landscape of major medical device manufacturers  

Global Robotic Surgery Market by Region (North America, Europe, Asia Pacific and ROW), by Product Type (Surgical Robot System, Instruments and Accessories and Services) - Outlook to 2022 

The report covers aspects such as robotic surgery market by its key segments including market size by regions, product type, application and brands.  

Contact Us :
Ken Research
Ankur Gupta
Head Marketing & Communications
[email protected]
+91-9015378249


SOURCE Ken Research


These press releases may also interest you

at 07:05
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you...

at 07:05
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...

at 07:05
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...

at 07:05
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the...

at 07:05
Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced a...



News published on and distributed by: